Skip to main content

Life Sciences & Medical Technology Group Hosts 2 Events During BIO Conference

BOSTON – June 13, 2018 –The Life Sciences & Medical Technology Group at global law firm Greenberg Traurig, LLP hosted attendees of the 2018 BIO International Convention at two events in the firm’s Boston office last week.

On Tuesday, June 5th, Greenberg Traurig hosted BIO attendees and local biotech and life science industry executives and investors for an evening networking reception.

On Thursday, June 7th, Greenberg Traurig sponsored and hosted the Boston Healthcare Drinks’ post-conference panel discussion, “Biotech Startup’s Choice: China vs. the US.” Moderated by Olive Health Technology Founder Wenjue Wu, the panel included the following industry experts:

  • Jingye Zhou, Co-founder and CEO, Eccogene, Inc.
  • Kathy He, VP of Corporate and Business Development, Abbisko Therapeutics
  • Stephan Lensky, COO/CBO, EpimAb Biotherapeutics, Inc.
  • Yide (Alan) Jiang, Chief Strategy Officer, Xtalpi Inc.

Welcome remarks were delivered by David J. Dykeman, Greenberg Traurig Boston shareholder, patent attorney, and co-chair of the firm’s global Life Sciences & Medical Technology Group and Boston Intellectual Property & Technology Group, and Dr. Fang Xie, Greenberg Traurig Boston shareholder and patent attorney. Prior to the panel discussion, Dr. Xie discussed key IP and corporate issues that biotech and medical device companies should be aware of when doing business in China. The seminar was followed by a networking reception.

"Greenberg Traurig is deeply involved in the biotechnology and life sciences industries, and we were pleased to host our many friends and industry contacts at these two events during the BIO International Convention in Boston," Dykeman said.

About Greenberg Traurig’s Life Sciences & Medical Technology Group

Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing. As part of the group, the Biotechnology and Pharmaceutical Industry Group focuses on advising clients in the biotechnology and pharmaceutical sectors.

About Greenberg Traurig’s Boston Office
Established in 1999, Greenberg Traurig’s Boston office is home to over 70 attorneys practicing in the areas of bankruptcy, corporate, emerging technology, energy, governmental affairs, intellectual property, labor and employment, life sciences and medical technology, litigation, public finance, and real estate. An important contributor to the firm's international platform, the Boston office includes a team of nationally recognized attorneys with both public and private sector experience. The team offers clients the value of decades of legal experience and hands-on knowledge of the local business community, supported by the firm's vast network of global resources.

About Greenberg Traurig, LLP
Greenberg Traurig, LLP (GT) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and is among the Top 20 on the 2017 Am Law Global 100. Web: Twitter: @GT_Law.